Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations

被引:10
|
作者
Peters, Tanja [1 ]
Soanes, Nigel [2 ]
Abbas, Maya [3 ]
Ahmad, Jabeen [4 ]
Delumeau, Jean-Christophe [5 ]
Herrero-Martinez, Esteban [6 ]
Paramananda, Melanie [7 ]
Piper, Johanna [8 ]
Smail-Aoudia, Fairouz [7 ]
van der Spuij, Willemijn [9 ]
Veizovic, Tina [10 ]
Winstanley, Gillian [11 ]
机构
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] AstraZeneca PLC, Cambridge, England
[3] Johnson & Johnson Middle East, Beirut, Lebanon
[4] Innovate PV, London, England
[5] Bayer Pharma, Singapore, Singapore
[6] AbbVie Ltd, Maidenhead, Berks, England
[7] Pierre Fabre Medicament, Boulogne, France
[8] Roche Prod Ltd, Welwyn Garden City, Herts, England
[9] Bristol Myers Squibb, Steinhausen, Switzerland
[10] Takeda, London, England
[11] Amgen Canada Inc, Mississauga, ON, Canada
关键词
D O I
10.1007/s40264-020-01008-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pharmaceutical legislation provides a legal framework to ensure the safe and effective use of medicines. This framework requires national regulatory authorities (NRAs) to establish and maintain a pharmacovigilance system (PV system) stating and enforcing the regulatory commitments that key stakeholders, including marketing authorisation holders (MAHs), are required to fulfil. In recent years, national legislative bodies and NRAs across the world have issued a significant amount of legislation and guidance enforcing the obligation to perform pharmacovigilance activities. In countries where the NRA is a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), safety management requirements are generally consistent with ICH guidelines. In a number of countries beyond this scope, requirements may deviate from internationally agreed standards, adding a substantial complexity and increasing burden on the stakeholders involved, whilst the benefit for patients' safety may not be evident. Committed to fulfilling safety-regulatory obligations in any country where a product licence is held, global pharmaceutical companies have accumulated a broad and deep experience acquired whilst meeting the expectations of a large array of diverse PV systems across the world. These range from sub-optimal frameworks, according to the World Health Organization (WHO) Global Benchmarking Tool, to highly effective resource-optimised PV systems. In order to support countries creating or further developing their PV systems, especially where infrastructure and resources are limited, the European Federation of Pharmaceutical Industries and Associations (EFPIA) International Pharmacovigilance Group (IPVG) has developed consensus recommendations consistent with harmonised standards for the development and step-wise implementation of key PV system components. These recommendations endorsed by the EFPIA membership constitute the focus of this review article.
引用
收藏
页码:17 / 28
页数:12
相关论文
共 50 条
  • [32] Development of consensus recommendations for the management of post-operative chylothorax in paediatric CHD
    Lion, Richard P.
    Winder, Melissa M.
    Amirnovin, Rambod
    Fogg, Kristi
    Bertrandt, Rebecca
    Bhaskar, Priya
    Kasmai, Cameron
    Holmes, Kathryn W.
    Moza, Rohin
    Vichayavilas, Piyagarnt
    Gordon, Erin E.
    Trauth, Amiee
    Horsley, Megan
    Frank, Deborah U.
    Stock, Arabela
    Adamson, Greg
    Lyman, Alissa
    Raymond, Tia
    Diaz, Isaura
    DeMarco, Alicia
    Prodhan, Parthak
    Fundora, Michael
    Aljiffry, Alaa
    Dewitt, Aaron G.
    Kozyak, Benjamin W.
    Greiten, Lawrence
    Scahill, Carly
    Buckley, Jason
    Bailly, David K.
    CARDIOLOGY IN THE YOUNG, 2022, 32 (08) : 1202 - 1209
  • [33] New guidelines and the development of an international consensus on recommendations for the antibiotic prophylaxis of infective endocarditis
    Shanson, David
    INTERNATIONAL HEALTH, 2010, 2 (04): : 231 - 238
  • [34] Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development
    Humphrey-Murto, Susan
    Crew, Richard
    Shea, Beverley
    Bartlett, Susan J.
    March, Lyn
    Tugwell, Peter
    Maxwell, Lara J.
    Beaton, Dorcas
    Grosskleg, Shawna
    de Wit, Maarten
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 1041 - 1046
  • [35] Clinic recommendations according to the Grading of Recommendations, Assessment, Development and Evaluation system
    Castillo-Bustos, J. A.
    Aguayo-Albasini, J. L.
    Flores-Pastor, B.
    REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION, 2014, 61 (02): : 61 - 63
  • [36] Development of Evidence-based Recommendations: Implications for Preparing Expert Consensus Statements
    Kwong, Joey S. W.
    Chen, Hao
    Sun, Xin
    CHINESE MEDICAL JOURNAL, 2016, 129 (24) : 2998 - 3000
  • [37] Malformations of cortical development: international consensus recommendations on diagnostic work-up
    Oegema, R.
    Barakat, T.
    Bahi-Buisson, N.
    Aronica, E.
    Conti, V.
    Zaki, M.
    Dobyns, W.
    Fry, A.
    Geis, T.
    Andres, D. Gomez
    Guerrini, R.
    Hehr, U.
    Jansen, A.
    Leventer, R.
    Amron, D.
    Mirzaa, G.
    Parrini, E.
    Pilz, D.
    Said, E.
    Soler, D.
    Stouffs, K.
    Valor, L. M.
    Reiner, O.
    Pogledic, I.
    Wilke, M.
    Mancini, G. M. S.
    Di Donato, N.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 398 - 399
  • [38] Development of Guideline and Macro Flow for Brazilian System of Pharmacovigilance: Basis for Decentralization
    M. O. Bittencourt
    M. F. Dias
    P. M. Figueiredo
    F. C. S. Cruz
    Drug Safety, 2008, 31 : 885 - 885
  • [39] Development, Validation and Implementation of an Active Electronic Pharmacovigilance System in Hospitalized Patients
    Ceschi, A.
    Hitz, P.
    Mueller, L.
    Bertoli, R.
    Piffaretti, V.
    DRUG SAFETY, 2018, 41 (11) : 1194 - 1195
  • [40] Development of Guideline and Macro Flow for Brazilian System of Pharmacovigilance: Basis for Decentralization
    Bittencourt, M. O.
    Dias, M. F.
    Figueiredo, P. M.
    Cruz, F. C. S.
    DRUG SAFETY, 2008, 31 (10) : 950 - 950